<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642313</url>
  </required_header>
  <id_info>
    <org_study_id>UOL-UIDNS-Mg-K</org_study_id>
    <nct_id>NCT04642313</nct_id>
  </id_info>
  <brief_title>Comparison of Mg Vs. K Supplementation on Insomnia in Diabetics</brief_title>
  <official_title>Comparison of Magnesium Versus Potassium and Their Combined Effect on Insomnia, Sleep Hormones, Insulin Resistance and Quality of Life Among Patients With Diabetes Mellitus&quot;.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lahore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lahore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insomnia is increasing alarmingly among the population. Micronutrient fluctuations have been&#xD;
      shown to effect insulin secretion, period of circadian cycle and quality of sleep in all&#xD;
      ages. This study is aimed to identify the impact of magnesium and potassium supplementation&#xD;
      on insomnia severity and duration, and insulin resistance, quality of life, sleep hormones,&#xD;
      serum magnesium and potassium levels. Moreover, the study will help to find out the link&#xD;
      between insomnia and micronutrients among patients of diabetes mellitus so that the burden of&#xD;
      the disease in the society could be reduced.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sleep is the essential component to maintain good health of an individual. Insomnia is&#xD;
      defined as a condition that affects an individual by inability to get sufficient quality&#xD;
      sleep or problem in maintaining sleep that is important for healthy functioning, performance&#xD;
      and well being. Insomnia can exist in healthy individual or comorbidly with other medical&#xD;
      diseases. Latest researches indicate that intolerance of glucose in the body, resistance to&#xD;
      insulin hormone, decreased acute response of insulin to glucose and increased chances of&#xD;
      having type 2 diabetes are reasons for reduced or interrupted sleep. Several electrolytes and&#xD;
      minerals influence the sleep cycle. Magnesium is important in regulation of central nervous&#xD;
      system excitability, through ion channel conductivity. Magnesium is a muscle relaxant and&#xD;
      inducer of the deeper sleep. Hypomagnesemia is a common feature in patients with type 2&#xD;
      diabetes. Although diabetes can induce hypomagnesemia, magnesium deficiency has also been&#xD;
      proposed as a risk factor for type 2 diabetes. Magnesium supplementation improves sleep&#xD;
      efficiency, sleep time and sleep onset latency, early morning awakening, and insomnia&#xD;
      objective measures such as the concentration of serum renin, melatonin, and serum cortisol,&#xD;
      in older adults. High ambient potassium levels have been shown to shorten the period of&#xD;
      circadian rhythms in a variety of organisms. Little is known about the effects of dietary&#xD;
      mineral nutrients on human sleep quality. Potassium depletion has been shown to cause glucose&#xD;
      intolerance, which is associated with impaired insulin secretion . Recently, there has been&#xD;
      growing evidence from both animal and human studies indicating that high sodium and low&#xD;
      potassium intakes are associated with a high risk of insulin resistance or diabetes.&#xD;
&#xD;
      The Study is aimed to:&#xD;
&#xD;
        1. To compare the effect of magnesium and/ or potassium on insomnia patients with diabetes&#xD;
           mellitus&#xD;
&#xD;
        2. To compare the gender and age based response to magnesium and/ or potassium on insomnia&#xD;
           patients with diabetes mellitus&#xD;
&#xD;
        3. To compare the effect of magnesium and/ or potassium on insulin resistance among&#xD;
           insomnia patients with diabetes mellitus&#xD;
&#xD;
        4. To compare the effect of magnesium and/ or potassium on sleep hormones among insomnia&#xD;
           patients with diabetes mellitus&#xD;
&#xD;
        5. To compare the effect of magnesium and/ or potassium on serum electrolytes (Mg, K) among&#xD;
           insomnia patients with diabetes mellitus&#xD;
&#xD;
        6. To compare the effect of magnesium and/ or potassium on quality of life (QOL) among&#xD;
           insomnia patients with diabetes mellitus MATERIAL AND METHODS Study Design: Randomized&#xD;
           Controlled Trial (single blind) Settings: Study will be conducted at&#xD;
&#xD;
      1. Akhuwat Health Services, Lahore Duration of Study: 18 months (after the approval of&#xD;
      synopsis) Sample Size: is 280 and with expected 20% drop out: 320 Sampling Technique: Non&#xD;
      probability purposive sampling&#xD;
&#xD;
      Inclusion Criteria:&#xD;
&#xD;
        -  Patients of diabetes mellitus with insomnia&#xD;
&#xD;
        -  Adult diabetic patients aged between 19 to 65 years&#xD;
&#xD;
        -  Patients of both genders&#xD;
&#xD;
        -  Diabetic patients of insomnia with or without antidiabetic drugs&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2020</start_date>
  <completion_date type="Anticipated">April 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be divided into 4 groups and will receive 4 different treatments at same time</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>It will be single blind study, Participants will not be aware of the treatment group, they are receiving</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of magnesium and/ or potassium supplementation on insomnia severity patients with diabetes mellitus</measure>
    <time_frame>60 days</time_frame>
    <description>Insomnia Severity Index (ISI) will be used to assess and categorize the insomnia among patients with diabetes mellitus, before and after the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of magnesium and/ or potassium on insulin resistance among insomnia patients with diabetes mellitus</measure>
    <time_frame>60 days</time_frame>
    <description>Homeostatic model assessment for insulin resistance (HOMA-IR) will be used to measure the insulin resistance before and after the Mg, K supplementation among insomniac patients with diabetes mellitus. Insulin will be measured through ELISA technique.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of magnesium and/ or potassium on sleep hormones (melatonin, cortisol) among insomniac patients with diabetes mellitus.</measure>
    <time_frame>60 days</time_frame>
    <description>Sleep hormones (melatonin, cortisol) will be measured before and after the intervention, through ELISA technique, among insomniac patients with diabetes mellitus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of magnesium and/ or potassium on serum electrolytes (Mg, K) among insomnia patients with diabetes mellitus</measure>
    <time_frame>60 days</time_frame>
    <description>Serum magnesium and/ potassium (in blood) will be measured through chemistry analyzer, before and after the Mg, K supplementation among insomniac patients with diabetes mellitus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of magnesium and/ or potassium on quality of life (QOL) among insomnia patients with diabetes mellitus</measure>
    <time_frame>60 days</time_frame>
    <description>WHOQOL-BREF will be used to measure quality of life before and after the Mg, K supplementation, among insomniac patients with diabetes mellitus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender and age based response to magnesium and/ or potassium on insomnia patients with diabetes mellitus</measure>
    <time_frame>60 days</time_frame>
    <description>Gender and age based responses of Mg, K supplementation will be compared among insomniac patients with diabetes mellitus</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect of magnesium and/ or potassium on quality liver function tests (LFTs) among insomnia patients with diabetes mellitus</measure>
    <time_frame>60 Days</time_frame>
    <description>Liver function tests (ALT, AST) will measured before and after the Mg, K supplementation among insomniac patients with diabetes mellitus</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Focus of Study is on Insomnia Among Diabetic Patients</condition>
  <arm_group>
    <arm_group_label>PLACEBO group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment: starch tablets (250 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium group: Magnesium gluconate (250 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Potassium group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Potassium group: Potassium chloride (250 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium + Potassium group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium + Potassium group: Magnesium gluconate (250 mg) + Potassium chloride (250 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnesium and/ or Potassium</intervention_name>
    <description>Magnesium and/ or potassium supplements will be provided to patients of diabetes mellitus with insomnia</description>
    <arm_group_label>Magnesium + Potassium group</arm_group_label>
    <arm_group_label>Magnesium group</arm_group_label>
    <arm_group_label>PLACEBO group</arm_group_label>
    <arm_group_label>Potassium group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Patients of diabetes mellitus with insomnia&#xD;
&#xD;
               -  Adult diabetic patients aged between 19 to 65 years&#xD;
&#xD;
               -  Patients of both genders&#xD;
&#xD;
               -  Diabetic patients of insomnia with or without anti-diabetic drugs&#xD;
&#xD;
               -  Diabetic patients of insomnia with or without Hypomagnesaemia&#xD;
&#xD;
               -  Diabetic patients of insomnia with or without Hypokalemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with the following conditions will not be included as participants,&#xD;
             patients of diabetes mellitus with insomnia with&#xD;
&#xD;
               -  Psychiatry reasons&#xD;
&#xD;
               -  Any hormonal treatment&#xD;
&#xD;
               -  CVD/ Other metabolic co-morbidities&#xD;
&#xD;
               -  History of acute liver injury (e.g., hepatitis) or severe cirrhosis&#xD;
&#xD;
               -  Renal diseases (renal stones, renal failure, dialysis)&#xD;
&#xD;
               -  Diabetic nephropathy&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Breast-feeding&#xD;
&#xD;
               -  Drug induced insomnia&#xD;
&#xD;
               -  Sleep disorders&#xD;
&#xD;
               -  Sleep-related movement disorders (restless leg syndrome)&#xD;
&#xD;
               -  Sleep-related respiratory disorders (sleep apnea)&#xD;
&#xD;
               -  Alcohol consumption&#xD;
&#xD;
               -  Cardiac respiratory disorders&#xD;
&#xD;
               -  Painful condition (apathy)&#xD;
&#xD;
               -  History of chronic liver disease&#xD;
&#xD;
               -  History of CKD&#xD;
&#xD;
               -  Participation in a study of an investigational medication or nutritional&#xD;
                  supplements/ medication within the past 90 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sidra Khalid</last_name>
    <phone>0923347498338</phone>
    <email>sidrakhalid.uaf@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shahid Bashir, PhD</last_name>
    <phone>092423200865</phone>
    <phone_ext>5967</phone_ext>
    <email>shahid.bashir@rsmi.uol.edu.pk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akhuwat Health Services</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waseem Abbas, FCPS</last_name>
      <phone>0923314527672</phone>
      <email>wasimhashmi14@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Lahore</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahid Bashir, PhD</last_name>
      <phone>0924232300865</phone>
      <phone_ext>5967</phone_ext>
      <email>shahid.bashir@rsmi.uol.edu.pk</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lahore</investigator_affiliation>
    <investigator_full_name>Sidra Khalid</investigator_full_name>
    <investigator_title>PhD Scholar</investigator_title>
  </responsible_party>
  <keyword>Insomnia, Diabetes Mellitus, Magnesium, Potassium, Melatonin, Cortisol, Insulin resistance, Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Patients data will be kept confidential and their identity will not be revealed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

